UNSPSC 41181533: Beta-2-glycoprotein iii immunological test system

In this classification, a Beta-2-glycoprotein iii immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Beta-2-glycoprotein iii. US FDA regulates Beta-2-glycoprotein iii immunological test system under 21 CFR 866.5440 and under FDA product code DDK.

UNSPSC 41181533 Beta-2-glycoprotein iii immunological test system is a Commodity code that does not reflect the actual work being solicited under it in recent state and local procurement activity. The recent opportunities tagged to this code span laboratory testing services, equipment repair and maintenance, spectrophotometer procurement, utility oil analysis, and capital equipment purchases — none of which align with immunological test systems or beta-2-glycoprotein testing. The mismatch suggests either systematic miscoding in state and local procurement systems or that this Commodity code is not actively used in current solicitation practice. No recent opportunities show substantive demand for beta-2-glycoprotein iii immunological test systems specifically.

The tagged opportunities instead reveal a fragmented market across multiple issuing bodies and service lines. Marion County, Oregon solicited laboratory testing and phlebotomy services under ITB SO1814-26 (due July 24, 2026), while the Texas Department of State Health Services sought laboratory equipment repair and maintenance for specific sterilization and washing units under IFB HHS0017421 (due July 6, 2026). Lubbock Power & Light issued an RFP for annual insulating oil testing services for electrical equipment (due July 22, 2026), and the City of Tampa issued an RFQ for a replacement spectrophotometer (due June 12, 2026). Activity is concentrated in Texas, Florida, Oregon, and Connecticut, with utilities, counties, cities, and health departments as primary buyers. Absent clear alignment between the code's nominal scope and actual procurement demand, this Commodity code presents minimal strategic opportunity for firms focused on immunological or serology testing systems.